{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T09:43:06Z","timestamp":1748079786367,"version":"3.37.3"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,15]],"date-time":"2023-04-15T00:00:00Z","timestamp":1681516800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,15]],"date-time":"2023-04-15T00:00:00Z","timestamp":1681516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Egypt Heart J"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>ST-segment elevation myocardial infarction (STEMI) is usually caused by a rupture in the atherosclerotic plaque, followed by platelet aggregation which ultimately leads to acute coronary artery occlusion. So far, few studies have investigated the effect of maintenance dose of Eptifibatide (glycoprotein IIb\/IIIa inhibitor) in STEMI patients who underwent primary percutaneous coronary intervention (PPCI). Therefore, in this study, we investigated the effect of maintenance dose of Eptifibatide in patients with STEMI who underwent PPCI. 264 patients who had acute chest pain suggestive of STEMI were entered in the study. All patients received the same dose of bolus dose of Eptifibatide in the cardiac catheterization laboratory. Then the patients were randomly divided into two groups, one group (<jats:italic>n<\/jats:italic>\u2009=\u2009147) received a maintenance dose of intravenous Eptifibatide (infusion of 2\u00a0\u03bcg\/kg\/min) and the other group (<jats:italic>n<\/jats:italic>\u2009=\u2009117) did not receive this treatment. Standard medical treatment of STEMI after PPCI was performed based on guidelines and the same in both groups. All patients were evaluated 1, 2, and 3\u00a0months after the start of treatment in terms of predicted outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The occurrence of 3-month major adverse cardiovascular events (MACE) between the case and control groups did not have a statistically significant difference (28.6% versus 35.0%;<jats:italic>P<\/jats:italic>value: 0.286). Also, investigations showed that the rate of re-infarction (<jats:italic>P<\/jats:italic>value: 0.024) and target lesion revascularization (<jats:italic>P<\/jats:italic>value: 0.003) was significantly lower in the group that received Eptifibatide infusion.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Eptifibatide maintenance dose infusion in patients who undergo PPCI in the context of STEMI, does not significantly reduce MACE, although it does significantly reduce re-infarction and target lesion revascularization. It also does not increase the risk of bleeding and cerebrovascular events<jats:bold>.<\/jats:bold><\/jats:p><\/jats:sec>","DOI":"10.1186\/s43044-023-00355-4","type":"journal-article","created":{"date-parts":[[2023,4,15]],"date-time":"2023-04-15T13:03:09Z","timestamp":1681563789000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Impact of maintenance dose of eptifibatide in patients with ST-segment elevation myocardial infarction who underwent primary percutaneous coronary intervention"],"prefix":"10.1186","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9721-4950","authenticated-orcid":false,"given":"Rozita","family":"Jalalian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5133-2481","authenticated-orcid":false,"given":"Babak","family":"Bagheri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4721-225X","authenticated-orcid":false,"given":"Jamshid","family":"Yazdani Charati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9667-248X","authenticated-orcid":false,"given":"Shahrnaz","family":"Khalaghi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4697-1182","authenticated-orcid":false,"given":"Mohammadreza","family":"Iranian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9105-7242","authenticated-orcid":false,"given":"Mahsa","family":"Mohammadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,4,15]]},"reference":[{"issue":"4","key":"355_CR1","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/S0002-9149(02)02489-X","volume":"90","author":"PG Steg","year":"2002","unstructured":"Steg PG, Goldberg RJ, Gore JM, Fox KA, Eagle KA, Flather MD, Sadiq I, Kasper R, Rushton-Mellor SK, Anderson FA, Investigators GRACE (2002) Baseline characteristics, management practices, and in-hospital outcomes of patients hospitalized with acute coronary syndromes in the Global Registry of Acute Coronary Events (GRACE). Am J Cardiol 90(4):358\u2013363","journal-title":"Am J Cardiol"},{"issue":"2","key":"355_CR2","doi-asserted-by":"publisher","first-page":"169","DOI":"10.2991\/jegh.k.201217.001","volume":"11","author":"U Ralapanawa","year":"2021","unstructured":"Ralapanawa U, Sivakanesan R (2021) Epidemiology and the magnitude of coronary artery disease and acute coronary syndrome: a narrative review. J Epidemiol Glob Health 11(2):169\u2013177","journal-title":"J Epidemiol Glob Health"},{"issue":"1","key":"355_CR3","doi-asserted-by":"publisher","first-page":"e000405","DOI":"10.1136\/openhrt-2016-000405","volume":"3","author":"A Doost Hosseiny","year":"2016","unstructured":"Doost Hosseiny A, Moloi S, Chandrasekhar J, Farshid A (2016) Mortality pattern and cause of death in a long-term follow-up of patients with STEMI treated with primary PCI. Open Heart 3(1):e000405. https:\/\/doi.org\/10.1136\/openhrt-2016-000405","journal-title":"Open Heart"},{"issue":"9078","key":"355_CR4","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/S0140-6736(96)07120-6","volume":"350","author":"AW Van t\u2019 Hof","year":"1997","unstructured":"Van t\u2019 Hof AW, Liem A, de Boer MJ, Zijlstra F (1997) Clinical value of 12-lead electrocardiogram after successful reperfusion therapy for acute myocardial infarction. Lancet 350(9078):615\u2013619","journal-title":"Lancet"},{"issue":"23","key":"355_CR5","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.1161\/01.CIR.97.23.2302","volume":"97","author":"AW Van t\u2019 Hof","year":"1998","unstructured":"Van t\u2019 Hof AW, Liem A, Suryapranata H, Hoorntje JC, de Boer MJ, Zijlstra F (1998) Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction: myocardial blush grade. Circulation 97(23):2302\u20132306","journal-title":"Circulation"},{"issue":"5","key":"355_CR6","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1161\/01.CIR.101.5.570","volume":"101","author":"EJ Topol","year":"2000","unstructured":"Topol EJ, Yadav JS (2000) Recognition of the importance of embolization in atherosclerotic vascular disease. Circulation 101(5):570\u2013580","journal-title":"Circulation"},{"issue":"Suppl 1","key":"355_CR7","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/s0167-5273(98)00284-8","volume":"68","author":"PR Eisenberg","year":"1999","unstructured":"Eisenberg PR, Ghigliotti G (1999) Platelet-dependent and procoagulant mechanisms in arterial thrombosis. Int J Cardiol 68(Suppl 1):S3-10. https:\/\/doi.org\/10.1016\/s0167-5273(98)00284-8","journal-title":"Int J Cardiol"},{"issue":"8","key":"355_CR8","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1517\/14656566.8.8.1147","volume":"8","author":"U Zeymer","year":"2007","unstructured":"Zeymer U (2007) The role of eptifibatide in patients undergoing percutaneous coronary intervention. Expert Opin Pharmacother 8(8):1147\u20131154","journal-title":"Expert Opin Pharmacother"},{"issue":"2","key":"355_CR9","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","volume":"39","author":"B Ibanez","year":"2018","unstructured":"Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, Caforio ALP, Crea F, Goudevenos JA, Halvorsen S, Hindricks G, Kastrati A, Lenzen MJ, Prescott E, Roffi M, Valgimigli M, Varenhorst C, Vranckx P, Widimsk\u00fd P, ESC Scientific Document Group (2018) 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 39(2):119\u2013177","journal-title":"Eur Heart J"},{"issue":"3","key":"355_CR10","first-page":"e4","volume":"145","author":"JS Lawton","year":"2022","unstructured":"Lawton JS, Tamis-Holland JE, Bangalore S, Bates ER, Beckie TM, Bischoff JM, Bittl JA, Cohen MG, DiMaio JM, Don CW, Fremes SE, Gaudino MF, Goldberger ZD, Grant MC, Jaswal JB, Kurlansky PA, Mehran R, Metkus TS Jr, Nnacheta LC, Rao SV, Sellke FW, Sharma G, Yong CM, Zwischenberger BA (2022) 2021 ACC\/AHA\/SCAI guideline for coronary artery revascularization: executive summary: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines. Circulation 145(3):e4\u2013e17","journal-title":"Circulation"},{"issue":"4","key":"355_CR11","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1067\/mhj.2001.113574","volume":"141","author":"JA De Lemos","year":"2001","unstructured":"De Lemos JA, Gibson CM, Antman EM, Murphy SA, Morrow DA, Schuhwerk KC, Schweiger M, Coussement P, Van de Werf F, Braunwald E, TIMI 14 Investigators (2001) Abciximab and early adjunctive percutaneous coronary intervention are associated with improved ST-segment resolution after thrombolysis: observations from the TIMI 14 trial. Am Heart J 141(4):592\u2013598","journal-title":"Am Heart J"},{"issue":"2","key":"355_CR12","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.jacc.2003.08.040","volume":"43","author":"H Kunichika","year":"2004","unstructured":"Kunichika H, Ben-Yehuda O, Lafitte S, Kunichika N, Peters B, DeMaria AN (2004) Effects of glycoprotein IIb\/IIIa inhibition on microvascular flow after coronary reperfusion. A quantitative myocardial contrast echocardiography study. J Am Coll Cardiol 43(2):276\u2013283","journal-title":"J Am Coll Cardiol"},{"key":"355_CR13","doi-asserted-by":"publisher","first-page":"204","DOI":"10.4103\/2277-9175.196831","volume":"5","author":"H Shariati","year":"2016","unstructured":"Shariati H, Sanei H, Pourmoghadas A, Salehizadeh L, Amirpour A (2016) Immediate outcomes of eptifibatide therapy during intracoronary stent implantation. Adv Biomed Res 5:204. https:\/\/doi.org\/10.4103\/2277-9175.196831","journal-title":"Adv Biomed Res"},{"issue":"8","key":"355_CR14","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1177\/1076029614529841","volume":"21","author":"S Topcu","year":"2015","unstructured":"Topcu S, Karal H, Kaya A, Bakirci EM, Tanboga IH, Kurt M, Aksakal E, Acikel M, Sevimli S (2015) The safety and efficacy of 12 versus 24 hours of tirofiban infusion in patients undergoing primary percutaneous coronary intervention. Clin Appl Thromb Hemost 21(8):783\u2013789","journal-title":"Clin Appl Thromb Hemost"},{"issue":"4","key":"355_CR15","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1111\/j.1365-2125.2010.03879.x","volume":"72","author":"DJ Schneider","year":"2011","unstructured":"Schneider DJ (2011) Anti-platelet therapy: glycoprotein IIb\u2013IIIa antagonists. Br J Clin Pharmacol 72(4):672\u2013682","journal-title":"Br J Clin Pharmacol"},{"issue":"9A","key":"355_CR16","doi-asserted-by":"publisher","first-page":"3E","DOI":"10.1016\/S0002-9149(99)00083-1","volume":"83","author":"RC Becker","year":"1999","unstructured":"Becker RC (1999) Thrombosis and the role of the platelet. Am J Cardiol 83(9A):3E-6E","journal-title":"Am J Cardiol"},{"issue":"23","key":"355_CR17","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","volume":"123","author":"R Mehran","year":"2011","unstructured":"Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, Kaul S, Wiviott SD, Menon V, Nikolsky E, Serebruany V, Valgimigli M, Vranckx P, Taggart D, Sabik JF, Cutlip DE, Krucoff MW, Ohman EM, Steg PG, White H (2011) Standardized bleeding definitions for cardiovascular clinical trials. A consensus report from the bleeding academic research consortium. Circulation 123(23):2736\u20132747","journal-title":"Circulation"},{"issue":"6","key":"355_CR18","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1161\/CIRCINTERVENTIONS.111.967802","volume":"5","author":"JM Stolker","year":"2012","unstructured":"Stolker JM, Cohen DJ, Kennedy KF, Pencina MJ, Lindsey JB, Mauri L, Cutlip DE, Kleiman NS, Evaluation of Drug-Eluting Stents and Ischemic Events (EVENT) Investigators (2012) Repeat revascularization after contemporary percutaneous coronary intervention. An evaluation of staged, target lesion, and other unplanned revascularization procedures during the first year. Circ Cardiovasc Interv 5(6):772\u2013782","journal-title":"Circ Cardiovasc Interv"},{"issue":"4","key":"355_CR19","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1093\/eurheartj\/ehl472","volume":"28","author":"G Montalescot","year":"2007","unstructured":"Montalescot G, Antoniucci D, Kastrati A, Neumann FJ, Borentain M, Migliorini A, Boutron C, Collet JP, Vicaut E (2007) Abciximab in primary coronary stenting of ST-elevation myocardial infarction: a European meta-analysis on individual patients\u2019 data with long-term follow-up. Eur Heart J 28(4):443\u2013449","journal-title":"Eur Heart J"},{"issue":"3","key":"355_CR20","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.ahj.2003.08.011","volume":"147","author":"DE Kandzari","year":"2004","unstructured":"Kandzari DE, Hasselblad V, Tcheng JE, Stone GW, Califf RM, Kastrati A, Neumann FJ, Brener SJ, Montalescot G, Kong DF, Harrington RA (2004) Improved clinical outcomes with abciximab therapy in acute myocardial infarction: a systematic overview of randomized clinical trials. Am Heart J 147(3):457\u2013462","journal-title":"Am Heart J"},{"issue":"6","key":"355_CR21","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/ccd.22349","volume":"75","author":"A Jeremias","year":"2010","unstructured":"Jeremias A, Vasu S, Gruberg L, Kastrati A, Stone GW, Brown DL (2010) Impact of abciximab on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction treated with primary stenting. Catheter Cardiovasc Interv 75(6):895\u2013902","journal-title":"Catheter Cardiovasc Interv"},{"issue":"14","key":"355_CR22","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1161\/CIRCULATIONAHA.108.818617","volume":"119","author":"J Mehilli","year":"2009","unstructured":"Mehilli J, Kastrati A, Schulz S, Fr\u00fcngel S, Nekolla SG, Moshage W, Dotzer F, Huber K, Pache J, Dirschinger J, Seyfarth M, Martinoff S, Schwaiger M, Sch\u00f6mig A, Bavarian Reperfusion Alternatives Evaluation-3 (BRAVE-3) Study Investigators (2009) Abciximab in patients with acute ST-segment\u2013elevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading: a randomized double-blind trial. Circulation 119(14):1933\u20131940","journal-title":"Circulation"},{"issue":"6","key":"355_CR23","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.jacc.2009.08.093","volume":"56","author":"U Zeymer","year":"2010","unstructured":"Zeymer U, Margenet A, Haude M, Bode C, Lablanche JM, Heuer H, Schr\u00f6der R, Kropff S, Bourkaib R, Banik N, Zahn R, Teiger E (2010) Randomized comparison of eptifibatide versus abciximab in primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction: results of the EVA-AMI trial. J Am Coll Cardiol 56(6):463\u2013469","journal-title":"J Am Coll Cardiol"},{"issue":"9247","key":"355_CR24","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1016\/S0140-6736(00)03400-0","volume":"356","author":"ESPRIT Investigators. Enhanced Suppression of the Platelet IIb\/IIIa Receptor with Integrilin Therapy","year":"2000","unstructured":"ESPRIT Investigators. Enhanced Suppression of the Platelet IIb\/IIIa Receptor with Integrilin Therapy (2000) Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet 356(9247):2037\u20132044","journal-title":"Lancet"},{"issue":"4","key":"355_CR25","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1111\/j.1540-8183.2011.00632.x","volume":"24","author":"M Mahmoudi","year":"2011","unstructured":"Mahmoudi M, Delhaye C, Wakabayashi K, Torguson R, Xue Z, Suddath WO, Satler LF, Kent KM, Pichard AD, Waksman R (2011) Integrilin in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction. J Interven Cardiol 24(4):351\u2013356","journal-title":"J Interven Cardiol"},{"issue":"4","key":"355_CR26","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1161\/CIRCINTERVENTIONS.108.847582.108.847582","volume":"2","author":"MR Le May","year":"2009","unstructured":"Le May MR, Wells GA, Glover CA, So DY, Froeschl M, Marquis JF, O\u2019Brien ER, Turek M, Thomas A, Kass M, Jadhav S, Labinaz M (2009) Primary percutaneous coronary angioplasty with and without eptifibatide in ST-segment elevation myocardial infarction: a safety and efficacy study of integrilin-facilitated versus primary percutaneous coronary intervention in ST-segment elevation myocardial infarction (ASSIST). Circ Cardiovasc Interv 2(4):330\u2013338","journal-title":"Circ Cardiovasc Interv"},{"issue":"11","key":"355_CR27","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1016\/j.cjca.2019.05.003","volume":"35","author":"A Karathanos","year":"2019","unstructured":"Karathanos A, Lin Y, Dannenberg L, Parco C, Schulze V, Brockmeyer M, Jung C, Heinen Y, Perings S, Zeymer U, Kelm M, Polzin A, Wolff G (2019) Routine glycoprotein IIb\/IIIa inhibitor therapy in ST-segment elevation myocardial infarction: a meta-analysis. Can J Cardiol 35(11):1576\u20131588","journal-title":"Can J Cardiol"}],"container-title":["The Egyptian Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43044-023-00355-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43044-023-00355-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43044-023-00355-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,10]],"date-time":"2023-12-10T18:54:20Z","timestamp":1702234460000},"score":1,"resource":{"primary":{"URL":"https:\/\/tehj.springeropen.com\/articles\/10.1186\/s43044-023-00355-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,15]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["355"],"URL":"https:\/\/doi.org\/10.1186\/s43044-023-00355-4","relation":{},"ISSN":["2090-911X"],"issn-type":[{"type":"electronic","value":"2090-911X"}],"subject":[],"published":{"date-parts":[[2023,4,15]]},"assertion":[{"value":"1 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The patients entered this project after obtaining oral and written informed consent. It should be noted that this study was approved by the Ethics Committee of Mazandaran University of Medical Sciences.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All of the authors mention that there is no conflict of interest in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"28"}}